BO25126: A study of patients with HER2-positive breast cancer (APHINITY)

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Cancer
Breast Cancer
Breast Cancer HER-2 Positive

Results
Download

Study results

LPS BO25126 APHINITY 6-year interim results November 2021 (PDF, 1.6 MB)

LPS BO25126 APHINITY Final Results June 2025 English (PDF, 0.9 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

BO25126: A study of patients with HER2-positive breast cancer (APHINITY)

Study results

LPS BO25126 APHINITY 6-year interim results November 2021 (PDF, 1.6 MB)

LPS BO25126 APHINITY Final Results June 2025 English (PDF, 0.9 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

Thank you

Request a call back

Find participating medical centers and current study status in each of them

BO25126: A study of patients with HER2-positive breast cancer (APHINITY)

For the latest version of this information please go to www.forpatients.roche.com